The startup develops targeted pain relief therapeutics specifically designed for patients recovering from musculoskeletal surgery, focusing on minimizing post-operative pain associated with orthopedic procedures. By enhancing recovery times and improving overall patient care, the company addresses the significant discomfort and complications that can arise after surgery.
Funding
$3.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Post-operative pain following musculoskeletal surgeries, particularly spinal fusions involving pedicle screws, is often severe and currently managed with high doses of opioids. These opioid treatments can lead to side effects that hinder recovery and prolong hospital stays.
Solution
SentryX is developing BR-003, an implantable, biodegradable hydrogel designed to provide localized pain relief following musculoskeletal surgery. The hydrogel releases bupivacaine, a local anesthetic, directly at the surgical site for an extended period of 72+ hours. BR-003 is designed for seamless integration with existing surgical workflows, such as spinal fusion, without altering the placement or function of existing implants like pedicle screws. By delivering targeted pain relief, SentryX aims to reduce or eliminate the need for systemic opioids, leading to faster recovery times and improved patient outcomes. The hydrogel is composed of biopolymers, ensuring biocompatibility and complete dissolution after the drug is released.
Target Audience
The primary target audience includes surgeons performing musculoskeletal surgeries, particularly spinal fusions, and hospitals seeking to reduce opioid use and improve post-operative patient recovery.
Features
- Implantable, biodegradable hydrogel for localized drug delivery.
- Sustained release of bupivacaine for 72+ hours, blocking pain signals at the source.
- Designed for co-implantation with existing surgical implants like pedicle screws.
- Biocompatible hydrogel composed of biopolymers that dissolve completely after drug release.
- Customizable release profiles to suit specific clinical needs and surgical procedures.
- Strong and elastic hydrogel suitable for minimally invasive surgery.
- Potential application in various surgical indications beyond spine surgery, including joint replacements and fracture fixation.